These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22430267)

  • 1. Financial relationships in economic analyses of targeted therapies in oncology.
    Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
    J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
    Friedberg M; Saffran B; Stinson TJ; Nelson W; Bennett CL
    JAMA; 1999 Oct; 282(15):1453-7. PubMed ID: 10535436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial conflicts of interest in economic analyses in oncology.
    Jang S; Chae YK; Majhail NS
    Am J Clin Oncol; 2011 Oct; 34(5):524-8. PubMed ID: 21441858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
    Bero L; Oostvogel F; Bacchetti P; Lee K
    PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of financial relationships in economic analyses of targeted therapies in oncology remains unclear.
    Conter HJ
    J Clin Oncol; 2012 Nov; 30(31):3895; author reply 3895. PubMed ID: 23008317
    [No Abstract]   [Full Text] [Related]  

  • 6. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.
    Riechelmann RP; Wang L; O'Carroll A; Krzyzanowska MK
    J Clin Oncol; 2007 Oct; 25(29):4642-7. PubMed ID: 17925561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conflict of interest in the debate over calcium-channel antagonists.
    Stelfox HT; Chua G; O'Rourke K; Detsky AS
    N Engl J Med; 1998 Jan; 338(2):101-6. PubMed ID: 9420342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.
    Perlis RH; Perlis CS; Wu Y; Hwang C; Joseph M; Nierenberg AA
    Am J Psychiatry; 2005 Oct; 162(10):1957-60. PubMed ID: 16199844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling in pharmacoeconomic studies: funding sources and outcomes.
    Garattini L; Koleva D; Casadei G
    Int J Technol Assess Health Care; 2010 Jul; 26(3):330-3. PubMed ID: 20584363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials.
    Lerner TG; Miranda Mda C; Lera AT; Ueda A; Briones B; Del Giglio A; Riechelmann R
    Contemp Clin Trials; 2012 Sep; 33(5):1019-22. PubMed ID: 22664644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
    Jang S; Chae YK; Haddad T; Majhail NS
    Breast Cancer Res Treat; 2010 Jun; 121(2):273-9. PubMed ID: 20352486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
    Fiorino T
    J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
    [No Abstract]   [Full Text] [Related]  

  • 13. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
    Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
    JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
    Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
    Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
    Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.
    Mitchell AP; Winn AN; Lund JL; Dusetzina SB
    Oncologist; 2019 May; 24(5):632-639. PubMed ID: 30728276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry sponsorship and authorship of clinical trials over 20 years.
    Buchkowsky SS; Jewesson PJ
    Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.